Immunogenic characteristics of the outer membrane phosphoporphrin as a vaccine candidate against Klebsiella pneumoniae

Gaowei Hu, Xue Chen, Wenhui Chu, Zhe Ma, Yingjie Miao, Xi Luo and Yongqian Fu*

Abstract
In recent years, Klebsiella pneumoniae (KP) has caused disease outbreaks in different animals, resulting in serious economic losses and biosafety concerns. Considering the broad antibiotic resistance of KP, vaccines are the most effective tools against infection. However, there is still no KP vaccine available in the veterinary field. Our results indicate that the highly conserved outer membrane phosphoporphrin (PhoE) of KP is immunogenic in mice and elicits high titers of antibodies that were shown to be specific for PhoE by immunoblotting. Immunization with PhoE also induced robust cell-mediated immunity and elicited the secretion of high levels of IFN-γ and IL-4, suggesting the induction of mixed Th1 and Th2 responses. Sera from PhoE-immunized mice induced significantly higher complement-mediated lysis of KP cells than did sera from the PBS control mice. Finally, mice immunized with PhoE were significantly protected against KP challenge, with better survival and a reduced visceral bacterial load. Our data underscore the great potential of PhoE as a novel candidate antigen for a vaccine against KP infection.

Keywords: Klebsiella pneumoniae, phosphoporphrin, immune responses, subunit vaccine

Introduction
Klebsiella pneumoniae (KP) is an important Gram-negative zoonotic opportunistic pathogen belonging to the family Enterobacteriaceae [1]. It can infect both humans and a broad spectrum of farm animals, such as pigs, cows, chickens and fishes, leading to pneumonia, meningitis, liver abscess, inflammation of the urinary tract, wound infections and even sepsis. Consequently, KP infections result in great economic losses and pose a great threat to public health [2–4].

The most effective drugs against bacterial pathogens are antibiotics, but KP produces extended-spectrum β-lactamases (ESBL) and is resistant to many clinical antibiotics, such as aminoglycosides, sulfamethoxazole, fluoroquinolones, and trimethoprim, which brings a great challenge to the prevention and control of KP infection [5]. Moreover, KP can also spread drug resistance genes into other strains through plasmid-mediated transmission [6, 7].

Given the increasing multidrug resistance and the reduced pipeline of new antibiotics in development, vaccination is one of the most attractive strategies for controlling infectious diseases and has been practiced for many years [8]. Early inactivated KP vaccines were developed and their immunogenicity was evaluated using rabbit models. However, inactivated vaccines require more than five vaccinations to produce a satisfactory serological response [9]. On the other hand, live attenuated vaccines suffer from complex technical production requirements and potential biosafety concerns [10]. Although capsular polysaccharides are good antigens for vaccine production and their conjugate vaccines are proven effective against infections caused by KP, the resulting protection was often short-lived [11].
Additionally, a siderophore receptor protein-based vaccine was used to reduce bovine mastitis caused by KP [12], but there is still no broadly applicable vaccine against KP infection in the veterinary field [13, 14].

Outer membrane proteins are located at the bacterial surface, and many of them are important antigens that can induce strong immune protection against infection [5]. A previous study used recombinant OmpK17 and OmpK36 as vaccine candidates against lung infection and sepsis caused by KP in murine models, but these vaccines only produced a maximal survival rate of 60% following challenge [16]. Porins are a class of outer membrane proteins that are vital for Gram-negative bacteria, and often act as diffusion channels responsible for the transport of certain hydrophilic nutrients [17]. The outer membrane phosphoporin (PhoE) of KP is the main passage for many antibiotics, and its altered expression was found to be related to antibiotic resistance [18]. Outer membrane porins are also involved in interactions with the host immune system [19, 20]. In addition, PhoE of E. coli was used as a carrier for the display of foreign antigenic determinants on the bacterial cell surface [21]. However, the immunogenicity of KP PhoE was unknown prior to this study.

Here, the immunogenicity of KP PhoE was predicted using bioinformatic tools and confirmed by experimental means. Recombinant PhoE protein induced strong humoral and cellular immune responses in mice, conferring protection against KP challenge. Taken together, the results indicate that PhoE is a promising candidate antigen for a vaccine against KP infection.

Materials and methods

Bacterial strains

The Klebsiella pneumoniae strain CVCC4080 was purchased from China Institute of Veterinary Drug Control (Beijing, China). The clinical isolate KPLYC2 was isolated from a diseased large yellow croaker and identified by 16S rDNA sequencing (GenBank: MT953921) and the standard strain ATCC700603 was kept in our laboratory. Pseudomonas aeruginosa (P. aeruginosa, ATCC27853) and E. coli str. K-12 substr. MG1655 were purchased from Beina biology-Henan industrial microbial strain engineering technology research center (Henan, China).

Sequence alignment, structural simulation and immunogenicity prediction

The amino acid sequences of PhoE homologs from 10 KP reference strains (GenBank accession nos. CDO13009.1, CDQ53146.1, QQE25821.1, QQL34782.1, AYQ65485.1, QRC13586.1, QOT93368.1, QLI92047.1, QLA30035.1, and CCI7867.1) were retrieved from NCBI GenBank sequence database and aligned using the MultAlin online server to analyze their conservation. Structural homology modeling of PhoE was conducted using the Swiss-Model online server. The external regions were predicted by calculating the surface probability index in DNASTAR software and were indicated by black frames. Antigenicity of PhoE was evaluated using the online server VaxiJen v.2.0 for prediction of protective antigens and subunit vaccines regardless of the sequence length [22]. Threshold scores of more than 0.5 were assumed to indicate probable antigens.

PCR amplification and plasmid construction

The phoe gene (GenBank: M28295) without signal peptide sequences (containing 63 nucleoside acid–base) was amplified using the forward primer 5’-CGCGGA TCCATGGCAGAATTTAAT-3’ with a BamHI site (underlined) and the reverse primer 5’-CCGCTCGAG TCAGAACTGTTAGGTCAATG-3’ with an Xhol site (underlined). The phoe gene was PCR-amplified using the genomic DNA of CVCC4080 as the template. The PCR reaction was carried out with reference to another study [20]. The PCR product with a size of 1065-bp was subcloned into the pET-28a vector with a His-tag. The recombinant plasmid was named as pET28a-phoe, and confirmed by double restriction enzymes digestion and DNA sequencing.

Expression and purification of recombinant protein

Recombinant PhoE was expressed according to a previous study [20], with minor modifications as follows. Briefly, the plasmid pET28a-phoe was used transform competent cells of E. coli BL21 (DE3), and a positive clone was picked from the plate and grown overnight in Luria–Bertani medium with kanamycin. When the OD600 of the bacterial culture reached 0.8, expression of PhoE was induced with 1 mM Isopropyl β-d-1-thiogalactopyranoside (IPTG, Sigma) and continued at 28 °C overnight. After induction, bacteria cells were harvested by centrifugation and resuspended in lysis buffer (137 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4, 2 mM KH2PO4, 0.1% Triton-X100, pH = 8.0). Then, the cells were ruptured and cell lysates cleared by centrifugation (12 000 × g for 25 min at 4 °C). Protein purification was performed as described previously [23]. The final protein concentration of PhoE was quantified using a Bicinchoninic Acid Protein Assay Kit (Sangon Biotech, Shanghai, China). The molecular weight and purity of the PhoE was examined by 12% sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE), after which the protein bands were transferred onto NC membranes (Sangon Biotech, Shanghai, China). Western blot was conducted as described in another study [24]. For blotting, the purified protein was detected using a primary
monoclonal antibody against the His tag (Roche, Basel, Switzerland) with a 1:5000 dilution and a second antibody horseradish peroxidase (HRP)-conjugated goat anti-mouse IgG (Sangon Biotech, Shanghai, China), diluted 1:10 000. Finally, the membrane was developed using the HRP-ECL chemiluminescence reagent (Sangon Biotech, Shanghai, China).

Immunoization of mice
All animal experimental protocols and procedures were in accordance with the “Zhejiang province animal use nursing ethics guide”, and were approved by the animal ethics committee of Taizhou University (Approval No.: TZXY2021-012). Animals were housed in negative pressure micro-isolator enclosures and had access to normal chow ad libitum. Sixty female 6–8 weeks old BALB/c mice (Shanghai SLAC Laboratory Animal Co., Ltd, China) were randomly assigned to three groups of 20 mice each and fed for 1 week. Before conducting the immunization experiment, the mouse sera were confirmed to be negative for antibodies against KP by indirect ELISA (iELISA, described in following section). Mice in groups 1 and 2 were subcutaneously injected with 100 µL of a solution containing 10 µg of purified PhoE mixed with Freund’s adjuvant at a 1:1 (v/v) ratio or inactivated whole bacteria (CVCC4080, 1 × 10^6 CFU/mL, IWB) mixed with Freund’s adjuvant according to previous studies [24, 25]. As a control, mice in group 3 were mock-immunized with PBS only. Mice in all groups were injected 3 times at 2-week intervals (weeks 0, 2 and 4). To determine antibody responses, blood samples were collected at 14, 28 and 42 days after the first immunization and sera were separated and used for antibody titration by iELISA. Lymphocytes from spleens were collected from mice that were sacrificed 2 weeks after the last immunization and used for enzyme-linked immunospot (ELISPOT) analysis.

Western blot analysis
The PhoE was separated on a 12% acrylamide SDS-PAGE gel and was transferred onto a NC membrane. The membranes were blocked with 3% BSA for 2 h at 37 °C. After blocking, the membranes were washed three times with PBST buffer (137 mM NaCl, 2.7 mM KCl, 4.3 mM Na_2HPO_4, 1.4 mM KH_2PO_4, 1% Tween-20, pH = 7.4), and incubated with the mice sera at a 1:5000 dilution for 1 h at 37 °C, followed by incubation with a horseradish peroxidase (HRP)-conjugated goat anti-mouse IgG at a dilution of 1:10 000 for 1 h at 37 °C. After three washes with PBST, the specific bands were developed using the HRP-ECL chemiluminescence reagent (Sangon Biotech, Shanghai, China).

Indirect ELISA
Sera were tested by iELISA to detect specific antibodies against PhoE according to a previous study [26]. Briefly, 96 well plates were coated with 100 µL per well of a solution containing 1 µg of purified PhoE protein. The coated wells were blocked with 3% BSA for 2 h at 37 °C and incubated with the mouse sera at 1:5000 dilution, followed by the HRP-labeled anti-mouse IgG at a 1:10 000 dilution. The color was developed for 15 min in the dark and the reaction was stopped by adding 50 µL of 2 N sulfuric acid. The absorbance at 450 nm was measured using an ELISA plate reader (TECAN-M200, TECAN Group Ltd., Switzerland).

Cytokine assays by ELISPOT
The spleens were collected and the lymphocytes were isolated using mouse 1 x lymphocyte separation medium (Dakewe, Shenzhen, China). Production of interferon-gamma (IFN-γ) and interleukin (IL)-4 by cytokine-secretion cells [27] was determined using ELISPOT assays (R&D Systems, Minneapolis, MN, USA) following the manufacturer’s instructions. Splenocytes were stimulated with 10 µg of PhoE protein. Splenocytes plus medium alone served as a negative control and splenocytes with PMA+ionomycin were used as a positive control. The plate was incubated for 20 h at 37 °C in a humidified atmosphere comprising 5% CO_2. Then, the plates were blocked with biotin conjugated antibodies against IFN-γ or IL-4, followed by streptavidin-HRP. The numbers of spots were calculated by an immunospot ELISPOT reader (Bioreader 4000, BIO-Sys, Germany).

In vitro antibacterial test
This test was performed as described previously [23, 28] with minor modifications as follows. Sera isolated from the immunized mice were heat-inactivated in a 56 °C water bath for 1 h. Then, 10^6 CFU of bacteria (Klebsiella pneumoniae strains CVCC4080, KPLYC2 and ATCC700603) from log phase cultures (OD_600=1.0) were co-incubated with 1:100 dilutions of the heat-inactivated sera containing 25% guinea pig complement in a 50 µL reaction at 37 °C for various durations. The reaction was terminated by adding 950 µL of Luria Broth and the mixtures were spread on Luria Agar plates. Bacteria without sera were used as the control. Percent lysis was determined using the formula 100 – 100[(CFU of experimental wells)/(CFU of control wells without antisera)].
Challenge, survival, bacterial load determination and preparation of tissue sections

56 days after initial immunization, different groups of mice were administered an intraperitoneal injection comprising 100 μL PBS with $5 \times 10^6$ CFU of log-phase KP strain CVCC4080. The mortality in each group of mice was monitored daily for 10 days after challenge. The liver and lungs were harvested on day 5 post-infection. Organs were homogenized and lysed with 1% Triton-X100. To determine the bacterial load, the tissue homogenate was centrifuged at 3000 × g for 5 min, and the supernatant was serially diluted and spread on Luria Agar plates. All surviving mice were euthanized and the liver and lung tissues from different groups were fixed by immersion in 4% paraformaldehyde. After dehydration and embedding in paraffin wax, the samples were sectioned into slices of 3 μm thickness and then stained with hematoxylin for 3 min and eosin for 2 min. The slides were covered with cover glass and examined by light microscopy (Nikon eclipse 80i, Nikon, Japan).

Detection of cross-reactivity with other Enterobacteriaceae species by Western blot analysis

Bacterial outer membrane proteins (OMPs) were extracted from cultures of E. coli str. K-12 substr. MG1655, Pseudomonas aeruginosa, and KP CVCC4080 using a commercially available outer membrane protein extraction kit (BestBio, Shanghai, China) according to the manufacturer’s instructions. The concentration of extracted proteins was determined using a BCA assay kit (Sangon Biotech, Shanghai, China) according to the manufacturer’s instructions. The concentration of extracted proteins was determined using a BCA assay kit (Sangon Biotech, Shanghai, China) according to the manufacturer’s instructions. The concentration of extracted proteins was determined using a BCA assay kit (Sangon Biotech, Shanghai, China) according to the manufacturer’s instructions.

Statistical analysis

Graphs were drawn using GraphPad Prism Version 5 for windows (GraphPad Software, San Diego, CA, USA) and statistical analysis was conducted using SPSS 22.0 software (IBM Corp., USA). The statistical significance of differences in IgG titers, percent survival, and bacterial load in organs was determined using ANOVA followed by the least significant difference (LSD) test, and that of cytokine spot counts was determined using Tukey’s post-test. The difference was considered significant at $p < 0.05$. The data represent means ± SD from at least three independent experiments. The star symbol (*) indicates $p < 0.05$ and two stars (***) indicate $p < 0.01$.

Results

PhoE is conserved among different KP strains and was predicted to contain potential antigenic epitopes

Based on the sequence alignment, we found that the PhoE protein was highly conserved among different KP strains (Figure 1A). A highly conserved sequence will help the potential vaccine antigen maintain effectiveness against diverse or emerging strains. We used the online Swiss-Model server to simulate the 3D structure of PhoE based on 1pho.1.A. The structure was composed of a large number of β-turns and random coils (Figure 1B). The results showed that PhoE is a barrel-like protein and the surface contains many exposed flexible areas, which is suitable for the formation of antigenic epitopes. Through the analysis of surface probability and antigenic index parameters in DNASTAR software, the surface regions of phoE were predicted to encompass aa 26–30 (NKNAN), aa 43–55 (YFSDYDSKGDQGT), aa 65–73 (TQINDDLTG), aa 81–93 (FGNKTESDSSQK), aa 126–146 (DMFPEGGDSQATDNFMHTKR), aa 166–182 (DLTLQYQKNEGREKK), aa 195–210 (DFGSDDFAVSAAAYTSS), aa 236–240 (DFGGSDDFAVSAAAYTSS), aa 249–264 (ETRMTPIGFSAKFA), aa 272–279 (QYQFDGFGL), aa 289–301 (KGDIEGVGSED), and aa 325–339 (INQLKDSNKGLINDD), which therefore may contain dominant epitopes (Figure 1A). Accordingly, the potential antigenicity of PhoE was estimated to be 0.7708, which is significantly more than the threshold of 0.5.

Construction of a heterologous expression vector and preparation of purified protein

In order to investigate the immunogenicity of PhoE, the recombinant plasmid pET28a-phoE was constructed and confirmed by digestion with restriction enzymes followed by sequencing. After digestion, pET28a-phoE yielded the pET28a vector backbone and phoE gene fragment (Figure 2A). The recombinant PhoE protein (deletion of signal peptides aa 1–21) was highly expressed in E. coli in the form of inclusion bodies and purified using NTA-Ni affinity chromatography. The purified PhoE was examined by 12% acrylamide SDS-PAGE and exhibited an apparent size of 38.8 kDa, which was consistent with its theoretical molecular weight (Figure 2B). Western blot analysis revealed a specific band with a molecular weight of approximately 40 kDa corresponding to PhoE protein, while the negative control (total E. coli lysate containing pET28a empty vector) did not show a corresponding band at this position (Figure 2C).

PhoE is immunogenic and induces a humoral immune response

To test the antigenicity of purified PhoE, mice were vaccinated with PhoE or an inactivated bacterial formulation. There were no apparent adverse effects of the vaccination on mouse appearance or behavior and the serum isolated from the immunized mice was used for Western blot analysis and iELISA. The Western blot results showed that PhoE could be recognized by the mouse serum elicited by purified PhoE (Figure 3A). The results of iELISA
Figure 1 MultAlin server analysis of PhoE sequences from different KP strains and simulation of the 3D structure using Swiss-Model. A PhoE sequences from reference strains of KP downloaded from the GenBank database were aligned using the MultAlin server and analyzed using DNASTAR. The red letters represent identical amino acid residues among the different PhoE reference sequences. Amino acid residues encircled in black frames represented the external regions and possible immunogenic epitopes of PhoE. B The tertiary structure of PhoE was predicted using Swiss-Model.

Figure 2 Identification of pET28a-PhoE by restriction enzyme digestion and detection of purified PhoE by SDS-PAGE and Western blot analysis. A The recombinant plasmid was subjected to endonuclease digestion and identified by agarose gel electrophoresis; M: 1 kb DNA marker, 1: the pET28a-PhoE plasmid was double digested with restriction endonucleases BamHI and XhoI. B SDS-PAGE analysis of purified PhoE protein (38.8 kDa). M: Pre-stained protein size maker; expected PhoE protein is indicated in lane 1. C Western blot analysis of purified PhoE protein. The primary antibody was an anti-His tag monoclonal antibody, and the secondary antibody was an HRP-conjugated goat anti-mouse IgG. M: Pre-Stained Protein maker; the specific band of PhoE was present in lane 2, and lane 1 was the lysate of the strain carrying the empty pET28a vector.
indicated the presence of serum IgG against PhoE in the group vaccinated with either the purified PhoE or IWB on day 14. Antibody (IgG) titers increased until day 28 after the first immunization and peaked on day 42 in the immunized group, but not in the PBS group (Figure 3B). The antibody levels in both experimental groups were higher than those of the control group (PBS only; \( P < 0.01 \)). These results indicate that PhoE is immunogenic and capable of inducing specific IgG in mice.

**PhoE induces a cell-mediated immune response**

To test cell-mediated immune responses, the induction of IFN-γ and IL-4 production by PhoE was evaluated using ELISPOT assays. Splenocytes were isolated from the spleens of vaccinated mice and stimulated with PhoE. The results showed that positive IFN-γ and IL-4-secreting cells were only induced in the PhoE immunized group or the IWB positive control group (\( p > 0.05 \)), but not in the PBS negative control group (\( p < 0.01 \); Figures 4A and B and Additional file 1). This result indicated that PhoE elicited both Th1- and Th2-type cellular immune responses in mice.

**PhoE-specific antibodies can induce the complement-mediated lysis of different KP strains**

Complement activation in the circulation is a critical component of the innate arm of antibacterial immunity. To test whether PhoE-specific antisera from immunized mice can induce KP killing, bactericidal activity was tested in vitro. Anti-PhoE serum from mice could kill KP CVCC4080, with the mean lysis ratio reaching 80, 94, and 98% at 40, 80, and 160 min, respectively (Figure 5A). Additionally, we also investigated the bactericidal activity of anti-PhoE serum in another two KP strains, KPLYC2 and ATCC700603. The lysis ratios of these two strains reached almost 90% at 80 min and increased further with prolonged incubation (Figures 5B and C). By contrast, the sera from the mock-immunized PBS group failed to induce any KP lysis by 160 min. These results indicated that there was strong complement activation after immunization with PhoE, which might contribute to antibacterial immunity in vivo.

**PhoE induces protective immunity against KP challenge in vivo**

To evaluate the protective efficacy of PhoE as a candidate vaccine, we challenged the immunized mice with \( 5 \times 10^6 \) CFU of the CVCC4080 strain by intraperitoneal injection. IWB and PBS were used as positive and negative control, respectively. All mice in the PBS control group succumbed to infection within 10 days, while < 65% survival was observed in the IWB group. By contrast, the survival ratio of the PhoE-immunized mice reached 87% (Figure 6B). This suggested strong protective efficacy of PhoE-elicted immunity against KP challenge in mice.

![Figure 3](image_url) **Figure 3** PhoE-specific antibody responses in mice detected by Western blotting and iELISA. A Recognition of PhoE by mouse sera in a Western blot. Lane M: Pre-Stained Protein maker, lane 1 is the sample of purified PhoE protein; line 2 is the negative control of *E. coli* lysate containing the empty pET28a vector. For Western blot analysis, the primary antibody was the mouse serum isolated from the mice immunized with PhoE, the secondary antibody was an HRP-conjugated goat anti-mouse IgG. B Serum was tested for the presence of IgG antibodies by iELISA using PhoE as coating antigen. The absorbance of the developed HRP reaction was measured at 450 nm. Bars represent arithmetic means ± SD of antibody titers. **p < 0.01.
To investigate if the protection of the mice in the above experiment was due to reduced bacterial loads in the visceral organs, mice were infected with KP and organs were collected for isolation of KP cells. The PhoE-immunized mice showed significantly fewer live bacteria in the liver (mean of recovered bacterial load was 1544 CFU) and lungs (mean of recovered bacterial load was 1689 CFU) compared with the PBS group (means of recovered bacterial load were 3912 CFU and 5612 CFU for liver and lungs, respectively) and IWB-immunized mice (means of recovered bacterial load...
Figure 6 PhoE inoculation induced protection from KP challenge and reduced the visceral bacterial load. A Summary of the experimental scheme of organ recovery and survival assay. B BALB/c mice (n = 10/group) were immunized with PhoE, IWB or mock-immunized with PBS and challenged with 5 × 10⁶ CFU of CVCC4080 through intraperitoneal injection. The general condition of the animals was recorded every 12 h. Significance was calculated by comparing survival of the mice immunized with PhoE and mock-immunized with PBS using the Log-Rank Mantel Cox test. C, D The number of bacteria in visceral organs was determined 5 days after infection (n = 5/group) by spreading the organ homogenates on LB agar plates. **p < 0.01.
were 2583 CFU and 3517 CFU for liver and lungs, respectively) (Figures 6C and D).

After organ recovery, the lung and liver tissues were sliced into sections for histopathological examination. As shown in Figure 7, the PhoE-immunized mice infected with KP showed weak pathological changes in their lung and liver, including a slight increase of infiltration by neutrophils and macrophages compared with the PBS mock-immunization group (Figures 7B and D). By contrast, more severe pathological changes, such as diffuse hemorrhage, pulmonary and interstitial edema, widening, and structural destruction were observed in the PBS mock-immunized mice infected with KP (Figures 7A and C).

Cross-reactivity of anti-rPhoE antibodies with other Enterobacteriaceae species
Since phoE is an outer membrane protein that presents high similarity with other Enterobacteriaceae species, and especially *E. coli*, it is important to investigate the specificity of this protein as an immunogenic target. Here, cross-reactivity of anti-rPhoE antibodies was tested against OMPs of *E. coli* and *P. aeruginosa*. After extraction and solubilization, OMPs from different bacteria were analyzed by SDS-PAGE and Western blot analysis with anti-rPhoE polyclonal antibodies. The Western blot with proteins from *E. coli* str. K-12 substr. MG1655 and KP showed a band with about 38 kDa molecular weight. Nevertheless, no binding was observed for *P. aeruginosa* proteins (Figure 8). This result indicated that the anti-rPhoE polyclonal antibodies could cross react with *E. coli* str. K-12 substr. MG1655.

Discussion
KP is a common zoonotic opportunistic pathogen associated with infections that are increasingly leading to excess morbidity and mortality in farm animals in recent years [2, 3]. Considering the broad drug resistance of KP, vaccines are considered the most effective tool to reduce the incidence of infections. However, there are few vaccines that can be used to prevent KP infection in veterinary practice. With the development of vaccine research, various attempts have been made to identify new potential antigen candidates either by in silico methods or by genomic screening [14, 29].

In this study, we elucidated the immunogenicity of the outer membrane phosphoporin (PhoE) and evaluated its potential as a vaccine candidate. Since antigenic variability of proteins may compromise the efficacy of vaccines,
a high degree of antigenic conservation is a valuable attribute of vaccine candidates. Notably, high amino acid sequence conservation is found in many outer membrane proteins, which makes them ideal vaccine candidates [30]. Based on the sequence alignment, PhoE is a highly conserved protein that is widely distributed among different KP reference strains (Figure 1A). It contains many β-turns and random coils with many exposed flexible areas that are suitable for the formation of antigenic epitopes (Figure 1B). Thus, PhoE shares common structural features with its previously reported orthologous outer membrane porins OmpC and OmpF from pathogenic E. coli, OmpK36 from KP, and VP1243 from Vibrio [19, 20, 31]. The antigenicity of PhoE were estimated to be 0.7708, which is significantly higher than the threshold of 0.5. Moreover, the immunogenicity of OmpK36, a homolog of PhoE, has been confirmed in another study [32]. These data underscore the potential of PhoE as a vaccine candidate.

In order to confirm the immunogenicity of PhoE by experimental means, recombinant PhoE was expressed in E. coli and purified by nickel ion affinity chromatography (Figure 2). Following immunization with purified PhoE, high levels of specific IgG against PhoE in the mouse serum were detected by iELISA (Figure 3). The humoral immune response plays an important role in eliminating bacterial infection [33]. High IgG levels in the PhoE antiserum will ideally induce complement-mediated lysis of KP through the classical pathway [34]. Earlier studies reported that porins of KP can form a complex with C1q, the first component of the classical complement pathway, and thereby activate the complement cascade, while this was neither observed with other OMPs nor with rough LPS [35, 36]. The formation of porin-C1q complexes activates the classical complement pathway. Together with an activated alternative complement pathway, the result is the effective elimination of serum-sensitive KP strains [32]. This may to some extent explain the high protection against challenge with KP in the immunized mice. Alternatively, the PhoE-elicited serum may contain functional antibodies that prevent adhesion, whereas opsonizing antibodies facilitate killing by macrophages and the complement system. To gain more insights into the mechanisms of immunogenicity and protective efficacy, the role of PhoE in macrophage adhesion should be evaluated in future studies. However, protective serum antibodies may be crucial for individuals with compromised cellular immunity and under conditions leading to significant bacteremia during the late stages of the disease. Thus, immunization with PhoE not only induced a strong systemic antibody response, but the antibodies were protective in nature in the in vitro experiments (Figure 5). The extent to which this contributes to the actual protection of the host against KP infection needs to be determined further.

In addition, splenocytes proliferated vigorously in vitro and secreted large amounts of IFN-γ and IL-4, both in mice immunized with the PhoE and the IWB control (Figure 4A, B and Additional file 1). Therefore, PhoE could elicit cellular immunity, and this cellular immune response was activated by proliferation of Th1- and Th2-type cells. However, earlier studies have reported that cytotoxic T lymphocytes also contribute to the lysis of KP and help protect mice against infection [37]. Finally, mice immunized with PhoE were protected against subsequent bacterial challenge (Figure 6) and KP could significantly reduce the hemorrhage caused by Klebsiella pneumoniae in internal organs of immunized mice (Figure 7). These findings confirmed that a PhoE-based vaccine may protect against KP infection. The better performance of the recombinant PhoE protein as a vaccine candidate compared to IWB has a number of possible explanations. Firstly, the level of IL-4 induced by immunization with recombinant phoE was higher than that of the IWB group. IL-4 is produced by activated Th2 cells,
and serves to promote the humoral immune response, which in turn contributes to complement-mediated lysis [35]. Secondly, the generation of memory cells plays an important role in inducing a strong immune response following re-exposure to an antigen. Protein antigens are notable inducers of memory T-cells [38, 39]. In this study, mice were immunized with the recombinant phoE protein three times, which could induce efficient immune memory that was reactivated after challenge. By contrast, the inactivated vaccine group needed to be vaccinated more than three times to trigger a better level of immune memory. Finally, inoculation routes have a great impact on the immunogenicity of different types of vaccines. For inactivated vaccines, intramuscular injection may be the best route of vaccination [40]. Therefore, the protective effect of vaccines is closely related to antigen type, number of times the vaccination was repeated, and the vaccination route [41].

Since phoE is a membrane protein with sequence similarity to functional proteins of other Enterobacteriaceae species, especially E. coli, it is important to investigate the cross-reactivity of anti-rPhoE polyclonal antibodies with other Enterobacteriaceae bacteria. According to the sequence alignment, the PhoE homologs form other Enterobacteriaceae species had high similarity with that of KP (Additional file 2), reaching over 77% sequence identity according to DNAMAN analysis. Especially, E. coli str. K-12 substr. MG1655 presented more than 84% sequence similarity with PhoE of KP. Therefore, the cross-reactivity of anti-rPhoE antibodies with E. coli K-12 substr. MG1655 needs to be investigated. Based on the Western blot results, anti-rPhoE antibodies could indeed react with the outer membrane protein fraction of E. coli str. K-12 substr. MG1655 (Figure 8). E. coli and KP belong to the same family, Enterobacteriaceae, and their membrane proteins may share conserved epitopes. Pseudomonas aeruginosa was chosen because it is also a common opportunistic pathogen in skin, respiratory tract and digestive tract of humans and farm animals [42]. However, anti-phoE polyclonal antibodies did not recognize the OprF, a major porin of P. aeruginosa (12% amino acid sequence identity with PhoE of KP) [43].

While cross-reactivity may be advantageous for therapeutic purposes [44, 45], there is also a great concern of potential detrimental effects on host gut microbiota. A previous study of a vaccine against Acinetobacter baumannii based on recombinant BamA revealed the impact of cross-reactivity on the gut microbiota of animal models [46]. Nevertheless, Vieira de Araujo et al. recently demonstrated that the effect of immunization on the gut microbiota is mild and is likely not the result of cross-reactivity of antibodies against recombinant proteins with homologous proteins in gut bacteria. However, the potential effect of the phoE of KP as a vaccine candidate on the host microbiota needs further study in the future. Considering the potential risk of cross reaction with host gut microbiota, the vaccine must be used reasonably based on local epidemiological monitoring and accurate diagnosis in the future.

In conclusion, we evaluated the immunogenicity of the PhoE protein of KP by in silico analysis and confirmed it experimentally. Our results indicate that the conserved surface-exposed outer membrane protein PhoE could provide immune protection in mice, indicating its great potential as a new vaccine candidate against KP infection in farm animals. Nevertheless, the possibility of cross-reactivity with other species of Enterobacteriaceae among the animal gut microbiota must be considered before the development of a commercial vaccine in the future.

**Supplementary Information**

The online version contains supplementary material available at https://doi.org/10.1186/s13567-022-01023-2.

**Abbreviations**

KP: Klebsiella pneumoniae; phoE: phosphoporin; IFN-γ: interferon γ; IL-4: interleukin 4; ESBL: extended-spectrum β-lactamases; OmpK: outer-membrane protein K; IPTG: isopropyl β-D-1-thiogalactopyranoside; SDS-PAGE: sodium dodecyl sulfate polyacrylamide gel electrophoresis; NC: nitrocellulose; ECL: enhanced chemiluminescence; HRP: horseradish peroxidase; iELISA: indirect enzyme-linked immunosorbent assay; IWB: inactivated whole bacteria; ELIS-POT: enzyme-linked immunoassay; CFU: colony forming units; PBS: phosphate buffered saline; LSD: least significant difference; Th cell: Helper T cell.

**Additional file 1.** ELISpot assay of IFN-y and IL-4 secretion. After isolating spleen lymphocytes of mice from the rPhoE, IWB and PBS control groups, the purified rPhoE was added for stimulation, and the number of spots of IFN-γ and IL-4 secreting T cells was recorded. a. IFN-γ secreting T cells of rPhoE, IWB and PBS (control) groups after rPhoE antigen stimulation; b. IL-4 secreting T cells from the rPhoE, IWB and PBS (control) groups after rPhoE antigen stimulation.

**Additional file 2.** Alignment of PhoE sequences form KP and other Enterobacteriaceae species using the MultAlin server. PhoE sequences from KP reference strains, other Enterobacteriaceae species (Citrobacter freundii, Salmonella sp., E. coli) and P. aeruginosa downloaded from the GenBank database were aligned using the MultAlin server and analyzed using DNASTAR. The red letters represent identical amino acid residues among the different PhoE reference sequences. Blue letters indicate that the amino acid conservation at this position is poor. Black solid circles indicate that the amino acid residue at this position may be missing. The symbol "*" indicates any of “NDQEBZ” amino acid residues. The symbol "%" indicates either F or Y amino acid residues.

**Acknowledgements**

We thank Dr Ivan Hajnal for a critical reading and correction of the manuscript.

**Authors’ contributions**

GH conducted the animal trial, analyzed the data, and wrote the manuscript. CX and WC contributed to the animal feeding and sample collection. ZM, YM and XL assisted with the data analyses and the manuscript preparation. YF...
contributed to experiment design and manuscript amendment. All authors read and approved the final manuscript.

Funding
This work was supported by Zhejiang Provincial Key R&D Program of China (Grant No. 2021C02049), Zhejiang Provincial Natural Science Foundation of China (Grant Nos. LQ20C200014 and LQ19B060003), Taizhou Science and Technology Plan Project (Grant No. 21ywwa67) and Taizhou University Innovation and entrepreneurship training program for College Students (Grant No. S202110350115).

Availability of data and materials
The datasets produced and/or analyzed during the current study are available from the corresponding author on reasonable request.

Declarations

Ethics approval and consent to participate
All study procedures were approved by the Taizhou University (Approval No.: TZXY2021-012) and were in accordance with the “Zhejiang province animal use nursing ethics guide” (Zhejiang, China).

Competing interests
The authors declare that they have no competing interests.

Received: 8 October 2021 Accepted: 16 December 2021
Published online: 21 January 2022

References
1. Mobasseri G, Thong KL, Teh CSJ (2021) Genomic analysis revealing the
of Taizhou University (Approval No.: TZXY2021-012) and were in accordance
with the “Zhejiang province animal use nursing ethics guide” (Zhejiang, China).

2. Brisse S, Dujiken E (2005) Identification and antimicrobial susceptibility of
100 Klebsiella animal clinical isolates. Vet Microbiol 105:307–312

3. Cerdeira L, Silva KC, Fernandes MR, Ienne S, de Souza TA, de Oliveira GD,
Moreno AM, Lincopan N (2016) Draft genome sequence of a CTX-M
15-producing Klebsiella pneumoniae sequence type 340 (clonal complex
258) isolate from a food-producing animal. J Glob Antimicrob Resist
7:67–68

4. Yang Y, Zhang A, Lei C, Wang H, Guan Z, Xu C, Liu B, Zhang D, Li Q, Jiang
W, Pan Y, Yang C (2015) Characteristics of plasmids colothing 16S rRNA
methylases, CTX-M, and virulence factors in Escherichia coli and
Klebsiella pneumoniae isolates from chickens in China. Foodborne Pathog
Dis 12:873–880

5. Ur Rahman S, Ali T, Ali I, Khan NA, Han B, Gao J (2018) The growing
genetic and functional diversity of extended spectrum beta-lactamases.
Biomed Res Int 2018:951718

6. Wyres KL, Holt KE (2018) Klebsiella pneumoniae as a key trafficker of drug
resistance genes from environmental to clinically important bacteria. Curr
Opin Microbiol 45:131–139

7. Dunn SJ, Connor C, McNally A (2019) The evolution and transmission of
multi-drug resistant Escherichia coli and Klebsiella pneumoniae: the
complexity of plasmids and plasmids. Curr Opin Microbiol 51:51–56

8. Babiu LA (1999) Broadening the approaches to developing more effective
vaccines. Vaccine 17:1587–1595

9. Green JH, Pigott NE, Bolin RC, Harrell WK (1970) Use of acetone-dried vac-
cines for preparing capsular antiserum against the Klebsiella group and
the lyophilized of Klebsiella cultures. Appl Microbiol 20:416–420

10. Hsieh PF, Lin TL, Lee CZ, Tsai SF, Wang JT (2008) Serum-induced iron-
acquisition systems and TonB contribute to virulence in Klebsiella
pneumoniae causing primary pyogenic liver abscess. J Infect Dis
197:1717–1727

11. Jones RJ, Roe EA (1984) Vaccination against 77 capsular types of
Klebsiella aerogenes with polyclonal Klebsiella vaccines. J Med Microbiol
18:413–421

12. Gorden PJ, Kleinhenz MD, Ydstie JA, Brick TA, Slindem LM, Peterson MP,
Stauba DE, Burkhardt DT (2018) Efficacy of vaccination with a Klebsiella
pneumoniae siderophore receptor protein vaccine for reduction of Kleb-
siella mastitis in lactating cattle. J Dairy Sci 101:10398–10408

13. Ravinder M, Liao KS, Cheng YG, Pawar S, Lin TL, Wang JT, Wu CY (2020)
A synthetic carbohydrate–protein conjugate vaccine candidate against
Klebsiella pneumoniae serotype K2. J Org Chem 85:15964–15997

14. Choi M, Tennant SM, Simon R, Gross AS (2019) Progress towards the
development of Klebsiella vaccines. Expert Rev Vaccines 18:681–691

15. Lang H (2000) Outer membrane proteins as surface display systems. Int J
Med Microbiol 290:579–585

16. Hussein KE, Bahey-El-Din M, Sheweita SA (2018) Immunization with the
outer membrane proteins OmpK17 and OmpK36 elicits protection against
Klebsiella pneumoniae in the murine infection model. Microb Pathog 119:12–18

17. Benz R (1988) Structure and function of porins from gram-negative bacteria.
Annu Rev Microbiol 42:359–393

18. Rocker A, Lacey JA, Belousoff MJ, Wilkisch JJ, Strugnell RA, Davies MR,
Lithgow T (2020) Global trends in proteome remodeling of the outer
membrane modulate antimicrobial permeability in Klebsiella pneumoniae.
mbio. 11.e00603

19. Massari P, Ram S, Macleod H, Wetzler LM (2003) The role of porins in neis-
seral pathogenesis and immunity. Trends Microbiol 11:87–93

20. Liu C, Chen Z, Tan C, Liu W, Xu Z, Zhou R, Chen H (2012) Immunogenic
characterization of outer membrane porins OmpC and OmpF of
porcine enterointestinal pathogenic Escherichia coli. FEMS Microbiol Lett
337:104–111

21. Agterberg M, Tommassen J (1991) Outer membrane protein PhoE as a
carrier for the exposure of foreign antigenic determinants at the bacterial
cell surface. Antonie Van Leeuwenhoek 59:249–262

22. Doychinova IA, Flower DR (2007) Vaxjein: a server for prediction of pro-
tective antigens, tumour antigens and subunit vaccines. BMC Bioinform
8:4

23. Das S, Chowdhury R, Pal A, Okamoto K, Das S (2019) Salmonella typhi
outer membrane protein STIV is a potential candidate for vaccine
development against typhoid and paratyphoid fever. Immunobiology
224:371–382

24. Zhang H, Zhang H, Xiong B, Fan G, Gao Z (2019) Immunogenicity of
recombinant outer membrane porin protein and protective efficacy
against lethal challenge with Bordetella bronchiseptica in rabbits. J Appl
Microbiol 127:1646–1655

25. Wei G, Cai S, Wu Y, Ma S, Huang Y (2020) Immune effect of Vibrio harveyi
formalin-killed cells vaccine combined with chitosan oligosaccharide and
astrogaly polysaccharides in Pseuophisarum fuscoguttatum × δ Epineph-
lius fuscoguttatus. Fish Shellfish Immunol 98:186–192

26. Mehndinejadianski K, Bandehpour M, Hashemi A, Ranjbar MM, Taheri S, Jalali
SA, Mosaffa N (2019) In silico design and evaluation of Acinetetobacter
baumannii outer membrane protein a antigenic peptides as vaccine can-
didate in immunized mice. Iran J Allergy Asthma Immunol 18:655–663

27. Li Z, Zhang F, Zhang C, Wang C, Li R, Zhao X, Hao L, Ding J (2019)
Immunoinformatics prediction of OMP22 and BCS3P1 for designing
multi-epitope vaccine against Brucella. Mol Immunol 114:651–660

28. Ho DK, Jarraya H, Meri S (2010) Human complement factor H binds to outer
membrane protein Rck of Salmonella. J Immunol 185:1763–1769

29. Lundberg U, Senn BM, Schuler W, Meinke A, Hannner M (2013) Identifica-
tion and characterization of antigens as vaccine candidates against
Klebsiella pneumoniae: Hum Vacc Immunother 9:497–505

30. Rollauer SE, Sooreshjani MA, Noijan I, Buchanan SK (2015) Outer mem-
brane protein biogenesis in Gram-negative bacteria. Philos Trans R Soc Lond B Biol Sci 370:20150023

31. Gao Z, Ye C, Zhou L, Zhang Y, Ge Y, Chen W, Pan J (2020) Evaluation of
the beta-barrel outer membrane protein VP1243 as a candidate antigen
for a cross-protective vaccine against Vibrio infections. Microb Pathog
147:104419

32. Kurupati P, Ramachandran NP, Poh CL (2011) Protective efficacy of DNA
vaccines encoding outer membrane protein A and OmpK36 of Klebsiella
pneumoniae in mice. Clin Vaccine Immunol 18:82–88

33. Saidova BM, Kishov MG, Akhmedov DR (2003) [Comparative information
value of humoral immunity characteristics in some bacterial and viral
infections]. Zh Mikrobiol Epidemiol Immunol 50–54 (in Russian)

34. Seino J, Eveleigh P, Warnaar S, van Haarlem LJ, van Es LA, Daha MR (1993)
Activation of human complement by mouse and mouse/human chi-
meric monoclonal antibodies. Clin Exp Immunol 94:291–296
35. Alberti S, Marques G, Camprubi S, Merino S, Tomas JM, Vivanco F, Benedi VJ (1993) C1q binding and activation of the complement classical pathway by *Klebsiella pneumoniae* outer membrane proteins. Infect Immun 61:852–860

36. Alberti S, Rodriguez-Quinones F, Schirmer T, Rummel G, Tomas JM, Rosenbusch JP, Benedi VJ (1995) A porin from *Klebsiella pneumoniae*: sequence homology, three-dimensional model, and complement binding. Infect Immun 63:903–910

37. Lee WH, Choi HI, Hong SW, Kim KS, Gho YS, Jeon SG (2015) Vaccination with *Klebsiella pneumoniae*-derived extracellular vesicles protects against bacteria-induced lethality via both humoral and cellular immunity. Exp Mol Med 47:e183

38. Tawfik DM, Ahmad TA, Sheweita SA, Haroun M, El-Sayed LH (2017) The detection of antigenic determinants of *Acinetobacter baumannii*. Immunol Lett 186:59–67

39. Singh R, Capalash N, Sharma P (2017) Immunoprotective potential of BamA, the outer membrane protein assembly factor, against MDR *Acinetobacter baumannii*. Sci Rep 7:12411

40. Zeng C, Tang X, Du Y, Sheng X, Xing J, Zhan W (2018) Dynamic distribution of formalin-inactivated *Edwardsiella tarda* in olive flounder (*Paralichthys olivaceus*) post intramuscular injection. Vet Immunol Immunopathol 199:53–60

41. Herzog C (2014) Influence of parenteral administration routes and additional factors on vaccine safety and immunogenicity: a review of recent literature. Expert Rev Vaccines 13:399–415

42. Faure E, Kwong K, Nguyen D (2018) *Pseudomonas aeruginosa* in chronic lung infections: how to adapt within the host? Front Immunol 9:2416

43. Chevalier S, Bouffartigues E, Bodilis J, Maillot O, Lesouhaitier O, Feuillolley MGJ, Orange N, Dulfour A, Cornelis P (2017) Structure, function and regulation of *Pseudomonas aeruginosa* porins. FEMS Microbiol Rev 41:698–722

44. Vila-Farres X, Parra-Millan R, Sanchez-Encinales V, Varese M, Ayerbe-Algaba R, Bayo N, Guardiola S, Pachon-Ibanez ME, Kotev M, Garcia J, Teixido M, Vila J, Pachon J, Giralt E, Smani Y (2017) Combating virulence of Gram-negative bacilli by OmpA inhibition. Sci Rep 7:14683

45. Babu L, Uppalapati SR, Sripathy MH, Reddy PN (2017) Evaluation of recombinant multi-epitope outer membrane protein-based *Klebsiella pneumoniae* subunit vaccine in mouse model. Front Microbiol 8:1805

46. Vieira de Araujo AE, Conde LV, da Silva Junior HC, de Almeida Machado L, Lara FA, Chapeaurouge A, Pauer H, Pires Hardoim CC, Martha Antunes LC, Dlincourt Carvalho-Assef AP, Moreno Senna JP (2021) Cross-reactivity and immunotherapeutic potential of BamA recombinant protein from *Acinetobacter baumannii*. Microbes Infect 23:104801

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

---

**Ready to submit your research?** Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

Learn more [biomedcentral.com/submissions](http://biomedcentral.com/submissions)